摘要
目的评估贝伐单抗联合铂类治疗晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)的疗效性和安全性。方法检索Pubmed、Elsevier sciencedirect、CENTRAL、CNKI、CBM、万方、维普等国内外重要文献数据库,使用Review Manager5.2软件对贝伐单抗治疗晚期NSCLC的总缓解率、无疾病进展期、总生存期、不良反应、死亡率进行Meta分析。结果共纳入7篇文献,Meta分析表明:1高、低剂量贝伐单抗能显著提高铂类化疗治疗晚期NSCLC总缓解率(P<0.000 01),显著延长无疾病进展期(P<0.000 01);2高剂量贝伐单抗能显著延长铂类化疗治疗晚期NSCLC总生存期(P<0.000 01),低剂量则不能改善总生存期;3高、低剂量贝伐单抗均会增加铂类化疗治疗晚期NSCLC的不良反应发生率(P<0.05),且均不能降低死亡风险。结论贝伐单抗联合铂类化疗能明显改善晚期NSCLC的总缓解率、无疾病进展期及总生存期,但同时会增加不良反应的发生,且不能降低死亡率。
OBJECTIVE To evaluate the efficacy and security of bevacizumab combined with platinum in the treatment of advanced non-small-cell lung cancer（NSCLC）. METHODS Clinical literature of bevacizumab and platinum in treating NSCLC were collected from Pubmed, Elsevier sciencedirect, CENTRAL, CNKI, CBM, Wangfang and VIP etc. Review Manager 5.2 was used for Meta-analysis of overall remission, progression free survival, overall survival, adverse effects and death rate of advanced NSCLC treated with bevacizumab. RESULTS Seven papers were included. The Meta-anaylysis results suggested that 1high and low dose bevacizumab obviously improved overall remission rate and progression free survival of advanced NSCLC patients（P〈0.000 01）; 2high dose bevacizumab obviously prolonged overall survival of NSCLC patients（P〈0.000 01）, but low dose bevacizumab had no significant effect on ooverall survival; 3high and low dose bevacizumab could increase incidence of adverse effect without effect of motality. CONCLUSION Bevacizumab combined with platinum can obviously improve overall remission, progression free survival and overall survival of NSCLC patients, but it also increases incidence of adverse effects and can＇t reduce motality.
出处
《中国现代应用药学》
CAS
CSCD
2015年第11期1382-1388,共7页
Chinese Journal of Modern Applied Pharmacy
基金
国家自然科学基金青年项目(81302934)
浙江省科技厅钱江人才计划(2012R10063)
浙江省卫生厅医药卫生科技计划项目(2013KYA140)
关键词
贝伐单抗
非小细胞肺癌
铂类
化疗
META分析
肿瘤
bevacizumab
non-small-cell lung cancer
platinum
chemotherapy
Meta-analysis
tumor
